Menu
Recruiting NCT04161768

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Phase III Interventional Spontaneous Bacterial Peritonitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Norfloxacin, Itopride.
Who it may be relevant to
Registry conditions: Spontaneous Bacterial Peritonitis. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparative Study of Norfloxacin Versus Norfloxacin With Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Overview

Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Detailed description

Comparative Study of Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Interventions

  • Drug Norfloxacin
    Norfloxacin 400 mg daily
  • Drug Itopride
    Itopride 50 mg three times daily

Primary outcome measures

  • Number of bouts of recurrence during treatment. [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • cirrhotic patients with ascites who had previous episodes of SBP.

Exclusion criteria

  • 1\. Allergy or contraindication for the used drugs. 2. Recent antibiotics therapy in the previous 2 weeks. 3. Patients with hepatocellular carcinoma or other neoplasia. 4. Pregnant and lactating women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Sherief Abd-Elsalam — Tanta

Identifiers

NCT: NCT04161768 · SBP Management

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗